InMed Pharmaceuticals Inc. Quarterly Cost of Revenue in USD from Q4 2021 to Q3 2023

Taxonomy & unit
us-gaap: USD
Description
The aggregate cost of goods produced and sold and services rendered during the reporting period.
Summary
InMed Pharmaceuticals Inc. quarterly/annual Cost of Revenue history and growth rate from Q4 2021 to Q3 2023.
  • InMed Pharmaceuticals Inc. Cost of Revenue for the quarter ending September 30, 2023 was $788K, a 235% increase year-over-year.
  • InMed Pharmaceuticals Inc. Cost of Revenue for the twelve months ending September 30, 2023 was $2.98M.
  • InMed Pharmaceuticals Inc. annual Cost of Revenue for 2023 was $2.42M, a 344% increase from 2022.
Cost of Revenue, Trailing 12 Months (USD)
Cost of Revenue, Quarterly (USD)
Cost of Revenue, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2023 $2.98M $788K +$553K +235% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-14
Q2 2023 $2.42M $1.01M Apr 1, 2023 Jun 30, 2023 10-K 2023-09-29
Q1 2023 $841K +$714K +561% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-15
Q4 2022 $339K +$185K +121% Oct 1, 2022 Dec 31, 2022 10-Q 2023-02-17
Q3 2022 $235K Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q1 2022 $127K Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 $154K Oct 1, 2021 Dec 31, 2021 10-Q 2023-02-17
* An asterisk sign (*) next to the value indicates that the value is likely invalid.